New combo test could sharpen prostate cancer treatment choices

This study looks at whether a genetic test called the Genomic Prostate Score (GPS) can help doctors better decide which men with low- or intermediate-risk prostate cancer are good candidates for focal therapy—a treatment that targets only the cancerous part of the prostate. Researchers will review past data and tissue samples from about 241 men who had both an MRI and prostate surgery. The goal is to see if combining the GPS score with MRI results improves the ability to predict which cancers are likely to be more aggressive.